FDA Seeking To Minimize Litigation In Pediatric Guidance Development
Executive Summary
FDA is proceeding cautiously in its development of a companion guidance to the pediatric list issued May 20 because of potential litigation, CDER Associate Director for Policy Jane Axelrad indicated at a Food & Drug Law Institute conference on May 21.